Savvy Advisors Inc. Acquires 990 Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• Savvy Advisors Inc. increased its holdings in Eli Lilly and Company by 26.3% during the first quarter, owning 4,757 shares valued at approximately $3.93 million.
• The company's latest earnings report showed $6.31 earnings per share for the quarter, exceeding analysts' expectations, with a year-over-year revenue growth of 37.6%.
• Eli Lilly also announced a quarterly dividend of $1.50 per share with a dividend yield of 0.9%, payable on September 10th.

Savvy Advisors Inc. grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 26.3% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 4,757 shares of the company's stock after buying an additional 990 shares during the period. Savvy Advisors Inc.'s holdings in Eli Lilly and Company were worth $3,929,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of LLY. LaSalle St. Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company by 39.1% during the first quarter. LaSalle St. Investment Advisors LLC now owns 1,070 shares of the company's stock valued at $883,000 after purchasing an additional 301 shares during the last quarter. Nutshell Asset Management Ltd raised its holdings in shares of Eli Lilly and Company by 43.0% during the first quarter. Nutshell Asset Management Ltd now owns 4,990 shares of the company's stock valued at $4,121,000 after purchasing an additional 1,500 shares during the last quarter. Caisse Des Depots ET Consignations raised its holdings in shares of Eli Lilly and Company by 13.7% during the first quarter. Caisse Des Depots ET Consignations now owns 9,946 shares of the company's stock valued at $8,215,000 after purchasing an additional 1,198 shares during the last quarter. AlphaCore Capital LLC raised its holdings in shares of Eli Lilly and Company by 75.3% during the first quarter. AlphaCore Capital LLC now owns 3,331 shares of the company's stock valued at $2,751,000 after purchasing an additional 1,431 shares during the last quarter. Finally, Fayez Sarofim & Co raised its holdings in shares of Eli Lilly and Company by 12.2% during the first quarter. Fayez Sarofim & Co now owns 443,587 shares of the company's stock valued at $366,363,000 after purchasing an additional 48,290 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Eli Lilly and Company news, Director Jamere Jackson acquired 200 shares of the stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Price Performance

LLY traded down $15.71 during trading on Friday, hitting $625.15. 14,089,857 shares of the company traded hands, compared to its average volume of 4,833,475. The company has a market cap of $592.48 billion, a PE ratio of 40.86, a P/E/G ratio of 0.91 and a beta of 0.44. The stock's 50-day simple moving average is $774.10 and its two-hundred day simple moving average is $798.80. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 98.25%. Eli Lilly and Company's quarterly revenue was up 37.6% on a year-over-year basis. During the same period last year, the company posted $3.92 earnings per share. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 1.0%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Analyst Ratings Changes

Several research firms have recently weighed in on LLY. Morgan Stanley reissued an "overweight" rating and set a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their target price for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target on the stock. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $990.89.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.